Adiponectin increases insulin content and cell proliferation in MIN6 cells via PPARγ-dependent and PPARγ-independent mechanisms

Diabetes, Obesity and Metabolism

Volumn 14, Issue 11, 2012, Pages 983-989

  Rao, J R ^a,b   Keating, D J ^c   Chen, C ^d   Parkington, H C ^b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adiponectin; MIN6 cells; PPAR

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADIPONECTIN; ADIPONECTIN RECEPTOR; GENOMIC DNA; GLUCOSE; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEEDBACK SYSTEM; INSULIN RELEASE; INSULIN SYNTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; UPREGULATION; WESTERN BLOTTING;

EID: 84867139111     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01626.x     Document Type: Article

References (49)

1. Kausch C, Krutzfeldt J, Witke A et al. Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem Biophys Res Commun 2001; 280: 664-674.
2. Cha BS, Ciaraldi TP, Carter L et al. Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia 2001; 44: 444-452.
3. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000; 106: 467-472.
4. Kliewer SA, Forman BM, Blumberg B et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 1994; 91: 7355-7359.
5. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70: 341-367.
6. Fujiwara T, Wada M, Fukuda K et al. Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 1991; 40: 1213-1218.
7. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-1558.
8. Kemnitz JW, Roecker EB, Weindruch R, Elson DF, Baum ST, Bergman RN. Dietary restriction increases insulin sensitivity and lowers blood glucose in rhesus monkeys. Am J Physiol 1994; 266: E540-E547.
9. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193-203.
10. Iwamoto Y, Kuzuya T, Matsuda A et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991; 14: 1083-1086.
11. Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 56-59.
12. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100: 530-537.
13. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
14. Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 2002; 51: 2341-2347.
15. Dubois M, Pattou F, Kerr-Conte J et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000; 43: 1165-1169.
16. Kim HI, Kim JW, Kim SH, Cha JY, Kim KS, Ahn YA. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 2000; 49: 1517-1524.
17. Kim HI, Cha JY, Kim SY et al. Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells. Diabetes 2002; 51: 676-685.
18. Kim EK, Kwon KB, Koo BS et al. Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NF kappaB pathway. Int J Biochem Cell Biol 2007; 39: 1260-1275.
19. Xu ZK, Chen NG, Ma CY, Meng ZX, Sun YJ, Han X. Role of peroxisome proliferator-activated receptor gamma in glucose-induced insulin secretion. Acta Biochim Biophys Sin (Shanghai). 2006; 38: 1-7.
20. Kamon J, Yamauchi T, Terauchi Y, Kubota N, Kadowaki T. The mechanisms by which PPARgamma and adiponectin regulate glucose and lipid metabolism. Nippon Yakurigaku Zasshi 2003; 122: 294-300.
21. Maeda N, Takahashi M, Funahashi T et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
22. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769.
23. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-26749.
24. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
25. Steyn FJ, Boehme F, Vargas E et al. Adiponectin regulate growth hormone secretion via adiponectin receptor mediated Ca(2+) signalling in rat somatotrophs in vitro. J Neuroendocrinol 2009; 21: 698-704.
26. Nielsen R, Grontved L, Stunnenberg HG, Mandrup S. Peroxisome proliferator-activated receptor subtype- and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery. Mol Cell Biol 2006; 26: 5698-5714.
27. Leturque A, Brot-Laroche E, Le Gall M. GLUT2 mutations, translocation, and receptor function in diet sugar managing. Am J Physiol Endocrinol Metab 2009; 296: E985-E992.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
29. Yamauchi T, Nio Y, Maki T et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-339.
30. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K. Adiponectin and adiponectin receptors in obesity-linked insulin resistance. Novartis Found Symp. 2007; 286: 164-176.
31. Welters HJ, McBain SC, Tadayyon M, Scarpello JH, Smith SA, Morgan NG. Expression and functional activity of PPARgamma in pancreatic beta cells. Br J Pharmacol 2004; 142: 1162-1170.
32. Kawai T, Hirose H, Seto Y et al. Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma. Diabetes Res Clin Pract 2002; 56: 83-92.
33. Leesnitzer LM, Parks DJ, Bledsoe RK et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002; 41: 6640-6650.
34. Ahn KO, Lim SW, Yang HJ et al. Induction of PPAR gamma mRNA and protein expression by rosiglitazone in chronic cyclosporine nephropathy in the rat. Yonsei Med J 2007; 48: 308-316.
35. Pelzer T, Jazbutyte V, Arias-Loza PA et al. Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats. Biochem Biophys Res Commun 2005; 329: 726-732.
36. Bell DS. Beta-cell rejuvenation with thiazolidinediones. Am J Med 2003; 115 (suppl 8A): 20S-23S.
37. Finegood DT, McArthur MD, Kojwang D et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029.
38. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998; 95: 2498-2502.
39. El-Assaad W, Buteau J, Peyot ML et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 2003; 144: 4154-4163.
40. Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, Wheeler MB. Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem 2010; 285: 33623-33631.
41. Okamoto M, Ohara-Imaizumi M, Kubota N et al. Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia 2008; 51: 827-835.
42. Gu W, Li X, Liu C et al. Globular adiponectin augments insulin secretion from pancreatic islet beta cells at high glucose concentrations. Endocrine 2006; 30: 217-221.
43. Winzell MS, Nogueiras R, Dieguez C, Ahren B. Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem Biophys Res Commun 2004; 321: 154-160.
44. Staiger K, Stefan N, Staiger H et al. Adiponectin is functionally active in human islets but does not affect insulin secretory function or beta-cell lipoapoptosis. J Clin Endocrinol Metab 2005; 90: 6707-6713.
45. Rakatzi I, Mueller H, Ritzeler O, Tennagels N, Eckel J. Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 2004; 47: 249-258.
46. Lin P, Chen L, Li D et al. Adiponectin reduces glucotoxicity-induced apoptosis of INS-1 rat insulin-secreting cells on a microfluidic chip. Tohoku J Exp Med 2009; 217: 59-65.
47. Inoue Y, Tanigawa K, Nakamura S et al. Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats. Diabetes Res Clin Pract 1995; 27: 19-26.
48. Ishida H, Takizawa M, Ozawa S et al. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress. Metabolism 2004; 53: 488-494.
49. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-26749.